A Patient Journey Through Statin Intolerance

Slides:

Advertisements

Similar presentations

Statin Myopathy (AHA/ACC/NHLBI)

Advertisements

for patients with dyslipidemia & previous stroke/TIA

Formative Test.

Paul J Kovack, DO, FACC, FACOI

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

Optimizing Statin Therapy

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Drug induced myopathy Edition

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Patient 1: 53-Year-Old Man With CVD Risk Factors

American Heart Association Scientific Sessions

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statins and the Elderly Patient

Statin Selection in Special Patient Populations: A Case Challenge

What Do We Know About LDL-C?

Understanding Statin Metabolism

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

An Update on PCSK9 Inhibitors

A Pharmacist's Guide to PCSK9 Inhibitors:

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

My Approach to the Patient With Familial Hypercholesterolemia

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

PCSK9 Inhibitors and Statin Intolerance

Updates on Dyslipidemia

Achieving Lipid Targets With PCSK9 Inhibition

Lipids, the Heart, and the Kidney

in diabetic patients with mixed dyslipidemia

PCSK9 Inhibitors and Real-World Evidence

Presentation transcript:

A Patient Journey Through Statin Intolerance

Statin Intolerance

PRIMO Study Incidence of Muscle AEs

Statin Myalgia Index Score

Potential AEs of Statins

Predisposing Factors for Statin Intolerance

Factors Affecting Statin Rechallenge

Low Vitamin D and Myopathy

Effect of Coenzyme Q10 on Statin-Induced Myopathy

Statins: Approximate LDL-C-Lowering Efficacy

Statin Drug-Drug Interactions

Therapy for Statin Intolerance

Managing Statin-Associated Myopathy

Ezetimibe: LDL-C Lowering

Statin Rechallenge

Niacin

Ezetimibe: IMPROVE-IT

Bile Acid Sequestrants

PCSK9 Monoclonal Antibodies

GAUSS-3: Evolocumab in Statin Intolerance

ODYSSEY ALTERNATIVE: Alirocumab in Statin Intolerance

ODYSSEY ALTERNATIVE: Myopathy

Bempedoic Acid (ETC-1002)

Guidance for Use of PSCK9 Inhibitors*

Abbreviations

Abbreviations (cont)